Replies to post #150356 on Biotech Values

[masterlongevity]

THis is one of three collabarative prevention trials.

this one is called DIAN and is using Gantenerumab, Solanezumab, and LY2886721

The one announced several months ago is called API, and is using crenezumab

The last one left, which is probably the most significant is called A4. They have yet to announce, but i have to think 1 of the 4 above will be included. All of the JNJ/PFE AIP products are virtually dead